TheraB Medical announced on February 11 that it has been acquired by Natus Sensory, an ArchiMed company.
TheraB Medical is an East Lansing, Michigan-based innovator in wearable phototherapy technology for neonatal jaundice. Its flagship product, SnugLit, delivers comprehensive body coverage in the familiar form factor of an infant swaddle while eliminating the need for eye protection. Its design allows increased clinician and parent interaction, including breastfeeding, without interrupting therapy.
TheraB received FDA 510(k) clearance in January 2026 and is backed by various individual angel investors and funds, including Red Cedar Ventures, Healthcare Equity Angels, Michigan Rise, Gulf South Angels, Foster Lane Investments, Invest Detroit Ventures, Suncoast Ventures, Smartgate Ventures, 3S Ventures, BakerBridge Ventures and Wisconsin River Business Angels.
Natus Sensory is a global leader in sensory care, supporting clinicians across hearing, balance, vision and newborn care.
The acquisition will enable broader adoption of TheraB’s flagship product, SnugLit, and support Natus Sensory’s mission to provide comprehensive, family-centered care for newborns. Financial terms of the deal were not disclosed.
“This acquisition validates TheraB’s mission to improve outcomes for infants diagnosed with neonatal jaundice, while Natus Sensory’s global presence in the pediatric community will help expand access to SnugLit’s innovative phototherapy across hospitals and clinical settings,” said Chris Mathia, CEO of TheraB.
According to data captured in the LevinPro HC database, this marks the 16th Medical Device transaction of 2026. There were 86 Medical Device deals announced during 2025, 87 announced in 2024 and 112 announced during 2023.
